An Open-Label, Multicenter, Phase 1/1b Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 27 Sep 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs JANX 008 (Primary)
Indications Adenocarcinoma; Colorectal cancer; Ductal carcinoma; Head and neck cancer; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
Focus Adverse reactions; First in man
Sponsors Janux Therapeutics

07 May 2024 According to Janux Therapeutics' media release, an update on the data is expected in 2025.
26 Feb 2024 Interim results (as of 12 Feb 2024) published a Janux Therapeutics media release.
20 Feb 2024 According to Janux Therapeutics' media release, the company will host a virtual event discussing dose escalation data for EGFR-TRACTr JANX008 on February 2024 at 4:30PM ET.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com